Conference Coverage

VIDEO: CAR T cell axi-cel drives B-cell lymphomas into remission


 

REPORTING FROM ASH 2017

– In the ZUMA-1 trial, more than one-third of patients with refractory large B-cell lymphomas treated with the chimeric antigen receptor (CAR) T-cell product axicabtagene ciloleucel (Yescarta; axi-cel) had durable responses, with some patients having complete responses lasting more than 1 year after a single infusion.

Updated combined phase 1 and 2 results in 108 patients with diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, or transformed follicular lymphoma showed an objective response rate of 82% of patients – including 58% showing complete responses – after a median follow-up of 15.4 months.

In a video interview at the annual meeting of the American Society of Hematology, Sattva S. Neelapu, MD, from the University of Texas MD Anderson Cancer Center in Houston discusses the use of CAR T cells directed against the CD19 antigen in patients with relapsed/refractory B-cell lymphomas and describes efforts to improve responses while managing adverse events common to CAR T-cell therapies, notably cytokine release syndrome.

ZUMA-1 is supported by Kite Pharma, which developed axicabtagene ciloleucel, and the Leukemia & Lymphoma Society’s Therapy Acceleration Program. Dr. Neelapu reported receiving advisory board fees from the company.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

Recommended Reading

CAR T-cell therapy: Moving from cost to value
MDedge Hematology and Oncology
CAR T-cells gain ground against hematologic cancers
MDedge Hematology and Oncology
ASCT or novel therapies in early relapsing follicular lymphoma?
MDedge Hematology and Oncology
Updated ZUMA-1 data show durable CAR-T responses in B-cell lymphomas
MDedge Hematology and Oncology
MAVORIC: Mogamulizumab tops vorinostat in pretreated CTCL
MDedge Hematology and Oncology
Three-month response to CAR T-cells looks durable in DLBCL
MDedge Hematology and Oncology
Combo prolongs survival in lymphoma models
MDedge Hematology and Oncology
Inhibitor exhibits activity against range of lymphomas
MDedge Hematology and Oncology
CCSs have increased risk of hypertension
MDedge Hematology and Oncology
Method identifies effective treatments for leukemias, lymphomas
MDedge Hematology and Oncology

Related Articles